The lung cancer drug from Pfizer is expected to surpass $1 billion in sales

The company's medicine helped patients live longer without seeing their cancer progress, as most of them experienced that benefit for over five years.

Pfizer expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 after most patients treated for a form of lung cancer had no disease progression after five years.